The White House withdraws its nomination of Heidi Overton to lead the US Food and Drug Administration (FDA) ahead of a scheduled Senate health committee vote. Multiple outlets report the decision comes shortly before the committee considers whether she has enough support to advance.

Coverage provides context around the nomination’s momentum in Congress and the White House’s rationale for pulling the pick. The New York Times and The Hill describe the timing as tied to uncertainty about votes, with The Hill noting Republicans’ narrow one-vote majority on the committee and suggesting that losing one member would derail the nomination.

Outlets also frame the background differently. The Guardian emphasizes that Overton is a prominent abortion opponent and characterizes her as a “Trump loyalist,” linking the withdrawal to internal political considerations. Fox News and other outlets focus more narrowly on the immediate eve-of-vote nature of the withdrawal, while not detailing broader issues beyond the impending Senate panel vote.